摘要
目的探讨甘肃省金昌市第一人民医院大肠埃希菌感染的临床分布以及耐药情况,为临床合理选用抗菌药提供科学依据。方法应用WHONET5.4软件对200株临床分离大肠埃希菌进行分析。结果大肠埃希菌主要分布于泌尿道、伤口、呼吸道、血液等标本。大肠埃希菌产ESBLs株占47.5%,产AmpC酶者占19.0%,同时产ESBLs和AmpC酶者占9%。大肠埃希菌对亚胺培南、头孢西丁、哌拉西林-他唑巴坦、头孢哌酮-舒巴坦和阿米卡星耐药率低,分离自泌尿道的大肠埃希菌对呋喃妥因的耐药率较低,对其余抗菌药物耐药率较高,达40%～95%。结论治疗大肠埃希菌感染时,需根据细菌药敏试验结果及患者病情选用碳青霉烯类抗生素、β内酰胺类抗生素-β内酰胺酶抑制剂或联合应用阿米卡星或头霉素类抗生素。
Objective To investigate the distribution and drug resistance of E.coli in clinical settings.Methods WHONET 5.5 software was used to analyze the clinical and laboratory data of 200 clinical isolates of E.coli.Results The primary site of infection caused by E.coli was urinary tract,followed by wound,respiratory tract and blood.Production of extended β-lactamases(ESBLs)was positive in 47.5% of these E.coli.Production of cephalosporinase(AmpC enzyme)was found in 19.0% of the strains.And 9% of these E.coli strains produced both ESBLs and AmpC enzymes.These E.coli strains showed relatively lower resistance to imipenem,cefoxitin,cefoperazone-sulbactam,piperacillin-tazobactam,and amikacin.The E.coli isolates from urinary tract showed very lower resistance to nitrofurantoin,but higher resistance(40%-95%)to other antibiotics.Conclusions E.coli infections should be managed according to the results of antibiotic susceptibility testing and patient conditions.The rational treatment options include carbapenems,β-lactams/β-lactamase inhibitor,or combination with amikacin or cephamycins.
出处
《中国感染与化疗杂志》
CAS
2010年第6期477-478,共2页
Chinese Journal of Infection and Chemotherapy
关键词
大肠埃希菌
临床分布
耐药性
Escherichia coli
clinical distribution
drug resistance
